Pill or procedure?Patient preferences on beta-blockers as an alternative to endoscopic variceal screening during the COVID-19 pandemic  

作　　者：Zheng Che Jeremy Louissaint Ihab Kassab Elliot B.Tapper 

机构地区：[1]Department of Internal Medicine,University of Michigan,Ann Arbor,MI,USA [2]Division of Gastroenterology and Hepatology,University of Michigan,Ann Arbor,MI,USA [3]Gastroenterology Section,VA Ann Arbor Healthcare System,Ann Arbor,MI,USA

出　　处：《Gastroenterology Report》2022年第1期632-634,共3页胃肠病学报道（英文）

基　　金：E.B.T.is supported by NIDDK K23 DK117055。

摘　　要：Introduction Certain patients at low risk of clinically significant esophageal varices by Baveno criteria can safely avoid screening esophagogastroduodenoscopy(EGD)[1,2].However,regardless of variceal status,the PREDESCI study suggests that earlier betablocker(BB)use in compensated disease with clinically significant portal hypertension by hepatic venous pressure gradient may result in benefit by delaying the time to decompensated cirrhosis[3,4].This carries significant ramifications for future clinical guidelines and decision-making for whom we decide to initiate BB.

关 键 词：ESOPHAGEAL HEPATIC SCREENING 

分 类 号：R57[医药卫生—消化系统]